Table 1 Demographic and patient characteristics
From: Plasma markers in pulmonary hypertension subgroups correlate with patient survival
IPAH (n = 16) | CTD-PAH (n = 24) | CHD-PAH (n = 10) | CTEPH (n = 37) | HC (n = 18) | p value | |
|---|---|---|---|---|---|---|
Baseline clinical characteristics | ||||||
Gender, female (%) | 12 (75%) | 21 (88%) | 4 (40%) | 20 (54%) | 9 (50%) | |
Age, y | 54.3 ± 17.2 | 63.6 ± 11.8 | 41.0 ± 17.7 | 61.4 ± 14.2 | 31.6 ± 9.9 | < 0.0001 |
BMI, kg/m2 | 27.7 ± 8.0 | 27.1 ± 4.4 | 23.7 ± 4.8 | 28.8 ± 6.0 | 0.16 | |
NYHA class 3–4, n (%) | 12 (75%) | 15 (63%) | 3 (30%) | 17 (46%) | ||
6MWT, m | 350 ± 135 | 333 ± 122 | 426 ± 173 | 379 ± 129 | 0.35 | |
NT-pro BNP, pmol/L | 317 ± 467 | 519 ± 1037 | 65 ± 88 | 127 ± 199 | 0.07 | |
Underlying CTD | ||||||
SSc, n (%) | 20/24 (83%) | |||||
SLE, n (%) | 4/24 (17%) | |||||
Baseline right heart catheterization | ||||||
mPAP, mmHg | 58.9 ± 16.5 | 41.5 ± 12.5 | 43.11 ± 14.9 | 40.1 ± 12.6 | 0.0001 | |
mRAP, mmHg | 11.9 ± 6.7 | 10.4 ± 6.0 | 10.8 ± 6.2 | 9.6 ± 7.1 | 0.72 | |
Capillary wedge pressure, mmHg | 9.2 ± 4.2 | 12.9 ± 8.1 | 14.5 ± 6.6 | 12.3 ± 4.5 | 0.21 | |
PVR, wood units | 10.6 ± 3.9 | 6.0 ± 3.5 | 4.3 ± 2.9 | 5.3 ± 3.4 | 0.0002 | |
PH-Medication | ||||||
At baseline, n (%) | 0/16 (0%) | 0/24 (0%) | 0/10 (0%) | 0/37 (0%) | ||
At 1 year follow up | ||||||
No PH-medication | 0/13 (0%) | 0/11 (0%) | 2/6 (33%)3 | 3/19 (16%)5 | ||
Mono therapy, n (%) | 1/13 (8%)1 | 1/11 (9%)2 | 1/6 (17%)4 | 11/19 (58%) | ||
Duo therapy, n (%) | 6/13 (46%) | 9/11 (82%) | 3/6 (50%) | 5/19 (26%) | ||
Triple therapy, n (%) | 6/13 (46%) | 1/11 (9%) | 0/6 (0%) | 0/19 (0%) | ||
Immunomodulatory drugs | ||||||
At baseline, n (%) | 0/16 (0%) | 3/24 (13%) | 0/10 (0%) | 0/37 (0%) | ||
At 1 year follow up, n (%) | 0/13 (0%) | 3/11 (27%) | 0/6 (0%) | 0/19 (0%) | ||
Survival | ||||||
Death/lung transplant < 3 years | 2 (12.5%) | 8 (33.3%) | 0 (0%) | 6 (16.2%) | ||
Death/lung transplant > 3 years | 2 (12.5%) | 0 (0%) | 3 (30%) | 2 (5.4%) |